These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 35001477)

  • 21. Ultrarapid Lispro Demonstrates Similar Time in Target Range to Lispro with a Hybrid Closed-Loop System.
    Bode B; Carlson A; Liu R; Hardy T; Bergenstal R; Boyd J; Morrett S; Ignaut D
    Diabetes Technol Ther; 2021 Dec; 23(12):828-836. PubMed ID: 34270335
    [No Abstract]   [Full Text] [Related]  

  • 22. Long-term effectiveness of advanced hybrid closed loop in children and adolescents with type 1 diabetes.
    Piccini B; Pessina B; Casalini E; Lenzi L; Toni S
    Pediatr Diabetes; 2022 Dec; 23(8):1647-1655. PubMed ID: 36317539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glycemic control during Ramadan fasting in adolescents and young adults with type 1 diabetes on MiniMed™ 780G advanced hybrid closed‑loop system: A randomized controlled trial.
    Elbarbary NS; Ismail EAR
    Diabetes Res Clin Pract; 2022 Sep; 191():110045. PubMed ID: 35987309
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Comparison of Postprandial Glucose Control in the Medtronic Advanced Hybrid Closed-Loop System Versus 670G.
    Weinzimer SA; Bailey RJ; Bergenstal RM; Nimri R; Beck RW; Schatz D; Ambler-Osborn L; Schweiger DS; von dem Berge T; Sibayan J; Johnson ML; Calhoun P; Phillip M;
    Diabetes Technol Ther; 2022 Aug; 24(8):573-582. PubMed ID: 35363054
    [No Abstract]   [Full Text] [Related]  

  • 25. The Effect of Prior Continuous Glucose Monitoring Use on Glycemic Outcomes in the Pivotal Trial of the MiniMed
    Cordero TL; Garg SK; Brazg R; Bailey TS; Shin J; Lee SW; Kaufman FR
    Diabetes Technol Ther; 2017 Dec; 19(12):749-752. PubMed ID: 29148821
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial.
    Bergenstal RM; Nimri R; Beck RW; Criego A; Laffel L; Schatz D; Battelino T; Danne T; Weinzimer SA; Sibayan J; Johnson ML; Bailey RJ; Calhoun P; Carlson A; Isganaitis E; Bello R; Albanese-O'Neill A; Dovc K; Biester T; Weyman K; Hood K; Phillip M;
    Lancet; 2021 Jan; 397(10270):208-219. PubMed ID: 33453783
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-Effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes.
    Jendle J; Pöhlmann J; de Portu S; Smith-Palmer J; Roze S
    Diabetes Technol Ther; 2019 Mar; 21(3):110-118. PubMed ID: 30785311
    [TBL] [Abstract][Full Text] [Related]  

  • 28. One-year experience of hybrid closed-loop system in children and adolescents with type 1 diabetes previously treated with multiple daily injections: drivers to successful outcomes.
    Petrovski G; Al Khalaf F; Campbell J; Umer F; Almajaly D; Hamdan M; Hussain K
    Acta Diabetol; 2021 Feb; 58(2):207-213. PubMed ID: 33044604
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved Glycemic Outcomes With Medtronic MiniMed Advanced Hybrid Closed-Loop Delivery: Results From a Randomized Crossover Trial Comparing Automated Insulin Delivery With Predictive Low Glucose Suspend in People With Type 1 Diabetes.
    Collyns OJ; Meier RA; Betts ZL; Chan DSH; Frampton C; Frewen CM; Hewapathirana NM; Jones SD; Roy A; Grosman B; Kurtz N; Shin J; Vigersky RA; Wheeler BJ; de Bock MI
    Diabetes Care; 2021 Apr; 44(4):969-975. PubMed ID: 33579715
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimizing Hybrid Closed-Loop Therapy in Adolescents and Emerging Adults Using the MiniMed 670G System.
    Messer LH; Forlenza GP; Sherr JL; Wadwa RP; Buckingham BA; Weinzimer SA; Maahs DM; Slover RH
    Diabetes Care; 2018 Apr; 41(4):789-796. PubMed ID: 29444895
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 10-Day structured initiation protocol from multiple daily injection to hybrid closed-loop system in children and adolescents with type 1 diabetes.
    Petrovski G; Al Khalaf F; Campbell J; Fisher H; Umer F; Hussain K
    Acta Diabetol; 2020 Jun; 57(6):681-687. PubMed ID: 31953687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and glycemic outcomes of do-it-yourself AndroidAPS hybrid closed-loop system in adults with type 1 diabetes.
    Gawrecki A; Zozulinska-Ziolkiewicz D; Michalak MA; Adamska A; Michalak M; Frackowiak U; Flotynska J; Pietrzak M; Czapla S; Gehr B; Araszkiewicz A
    PLoS One; 2021; 16(4):e0248965. PubMed ID: 33819289
    [TBL] [Abstract][Full Text] [Related]  

  • 33. One Year Clinical Experience of the First Commercial Hybrid Closed-Loop System.
    Lal RA; Basina M; Maahs DM; Hood K; Buckingham B; Wilson DM
    Diabetes Care; 2019 Dec; 42(12):2190-2196. PubMed ID: 31548247
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of Extended Infusion Set Performance in Adults with Type 1 Diabetes: Infusion Set Survival Rate and Glycemic Outcomes from a Pivotal Trial.
    Brazg R; Garg SK; Bhargava A; Thrasher JR; Latif K; Bode BW; Bailey TS; Horowitz BS; Cavale A; Kudva YC; Kaiserman KB; Grunberger G; Reed JC; Chattaraj S; Zhang G; Shin J; Chen V; Lee SW; Cordero TL; Rhinehart AS; Vigersky RA; Buckingham BA
    Diabetes Technol Ther; 2022 Aug; 24(8):535-543. PubMed ID: 35263188
    [No Abstract]   [Full Text] [Related]  

  • 35. Prospective Analysis of the Impact of Commercialized Hybrid Closed-Loop System on Glycemic Control, Glycemic Variability, and Patient-Related Outcomes in Children and Adults: A Focus on Superiority Over Predictive Low-Glucose Suspend Technology.
    Beato-Víbora PI; Gallego-Gamero F; Lázaro-Martín L; Romero-Pérez MDM; Arroyo-Díez FJ
    Diabetes Technol Ther; 2020 Dec; 22(12):912-919. PubMed ID: 31855446
    [No Abstract]   [Full Text] [Related]  

  • 36. Switching from Suspend-Before-Low Insulin Pump Technology to a Hybrid Closed-Loop System Improves Glucose Control and Reduces Glucose Variability: A Retrospective Observational Case-Control Study.
    Lepore G; Scaranna C; Corsi A; Dodesini AR; Trevisan R
    Diabetes Technol Ther; 2020 Apr; 22(4):321-325. PubMed ID: 31617752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In-home use of a hybrid closed loop achieves time-in-range targets in preschoolers and school children: Results from a randomized, controlled, crossover trial.
    von dem Berge T; Remus K; Biester S; Reschke F; Klusmeier B; Adolph K; Holtdirk A; Thomas A; Kordonouri O; Danne T; Biester T
    Diabetes Obes Metab; 2022 Jul; 24(7):1319-1327. PubMed ID: 35373894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MiniMed 780G™ in 2- to 6-Year-Old Children: Safety and Clinical Outcomes After the First 12 Weeks.
    Pulkkinen MA; Varimo TJ; Hakonen ET; Harsunen MH; Hyvönen ME; Janér JN; Kiiveri SM; Laakkonen HM; Laakso SM; Wehkalampi K; Hero MT; Miettinen PJ; Tuomaala AK
    Diabetes Technol Ther; 2023 Feb; 25(2):100-107. PubMed ID: 36511831
    [No Abstract]   [Full Text] [Related]  

  • 39. Six-Month Glycemic Control with a Hybrid Closed-Loop System in Type 1 Diabetes Patients in a Latin American Country.
    Proietti A; Raggio M; Paz M; Rubin G; Kabakian M; Saleme A; Grosembacher L
    Diabetes Technol Ther; 2022 Mar; 24(3):220-226. PubMed ID: 34668782
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-World User and Clinician Perspective and Experience with MiniMed™ 780G Advanced Hybrid Closed Loop System.
    Kesavadev J; Basanth A; Krishnan G; Shankar A; Sanal G; Jothydev S
    Diabetes Ther; 2023 Aug; 14(8):1319-1330. PubMed ID: 37278948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.